Drug intelligence / Profile preview

DA-2803

Development stage: Phase 1
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-2803 is an investigational small molecule antiviral drug developed by Dong-A ST for the treatment of Hepatitis B. Its precise mechanism of action has not been defined or disclosed publicly. The drug is a new molecular entity and has undergone early-stage clinical development, including phase 1 trials in South Korea, where it was administered orally as a tablet to healthy volunteers to assess safety, tolerability, and pharmacokinetics. As of the latest updates, no approvals have been reported for any indication[1][2][3].

Other names: Tenofovir Alafenamide

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on DA-2803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-2803.

Explore the full profile